The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).
N. K. Venepalli
No relevant relationships to disclose
A. S. Hutchison
No relevant relationships to disclose
D. P. Carbone
No relevant relationships to disclose
D. H. Johnson
Consultant or Advisory Role - miRNA Therapeutics (U)
V. L. Keedy
No relevant relationships to disclose
W. Pao
No relevant relationships to disclose
A. Sandler
Consultant or Advisory Role - Cephalon
L. Horn
No relevant relationships to disclose